Naveen Pemmaraju, MD, discusses results from a phase I/II trial of tagraxofusp in patients with relapsed/refractory myelofibrosis, a disease with only one approved treatment option.
Recent Articles
Americans Owe $140 Billion in Medical Debt Sold to Collections Agencies
Americans owe $140 billion in medical debt that has been sold to collections agencies, according to research published in the Journal of the American...
FDA Supports Inclusion of Pregnant and Breastfeeding Women in Clinical Trials
Officials at the U.S. Food and Drug Administration (FDA) have announced their commitment to work with other regulators and industry to support the inclusion...
Cancer Death Rates Fell 1.4% More in Early Medicaid Expansion States
A new study published in the Journal of the National Cancer Institute (JNCI), cancer death rates declined more sharply in U.S. states that expanded...
Reader Responses: How would you manage this patient with T-cell large granular lymphocytic leukemia?
Here’s how readers responded to a You Make the Call question about management of a patient with T-cell large granular lymphocytic leukemia.
Disclaimer: ASH does...
Current Issue
August 2021 Volume 7 Issue 10
This issue explores hematologic conditions in athletes, blue top tube shortages, and more.